A drug patent lasts 20 years. In practice, pharmaceutical companies routinely extend monopoly pricing for decades longer. They do it through three strategies: evergreening (filing dozens of secondary patents around one molecule), pay-for-delay (paying generic competitors to stay off the market), and product hopping (replacing a drug with a barely modified version before generics arrive). These are legal, deliberate, and expensive for everyone except the companies that use them.

Evergreening: The Patent Thicket

When a company wins FDA approval for a new drug, the original composition patent is often already partway through its 20-year term. What follows is a second wave of patent filings. These secondary patents cover formulation changes, delivery devices, dosing regimens, salt forms, manufacturing processes, and new indications. Each one carries a full 20-year term. Each one can be listed in the FDA's Orange Book, where it serves as a tripwire against generic entry.

The scale is systemic. Sixty-six percent of patent applications for top-selling drugs were filed after FDA approval. Companies build thickets of 50 to 100 or more patents around a single molecule. The patent system treats a trivial coating change the same as a breakthrough discovery. Both get 20 years.

Humira: 130 Patents on One Drug

AbbVie's Humira (adalimumab) is the definitive case. The company filed more than 130 secondary patents around the drug. Fewer than 20 covered the core molecule. The composition patent expired in 2016. US biosimilar competition did not arrive until 2023, seven years later.

AbbVie settled with every biosimilar applicant, granting licenses timed to preserve its revenue window. The thicket worked exactly as designed: each biosimilar manufacturer faced the prospect of litigating against dozens of patents simultaneously, with the 30-month regulatory stay triggered by each challenge. Settlement was cheaper than fighting.

Cumulative Humira revenue exceeded $200 billion. The estimated cost of delayed biosimilar savings was $7.6 billion per year. For seven years, patients and insurers paid monopoly prices on a drug whose core patent had already expired.

Tricor: The Serial Reformulation

Abbott's cholesterol drug Tricor (fenofibrate) followed a different playbook. Abbott released three sequential reformulations: Tricor-1 (capsule), Tricor-2 (tablet), Tricor-3 (different tablet). Each reformulation was timed to coincide with generic entry on the prior version. Abbott switched 97% of prescriptions to the new version before generics became available for the old one. By the time a generic arrived, the market had moved. Cost to the healthcare system: roughly $700 million per year.

OxyContin and Sarafem

Purdue Pharma filed an abuse-deterrent reformulation patent on OxyContin that extended effective protection to 2030. The reformulation made the tablet harder to crush, a legitimate safety improvement that doubled as a patent extension vehicle.

Eli Lilly isolated the R-enantiomer of Prozac (fluoxetine), rebranded it as Sarafem for premenstrual dysphoric disorder, and obtained a fresh patent on what was effectively the same molecule. The revenue stream continued past Prozac's expiry.

Pay-for-Delay: Buying Off the Competition

A brand-name manufacturer pays a generic company to abandon its patent challenge and delay market entry. The generic receives a guaranteed payment, often tens or hundreds of millions of dollars. The brand preserves monopoly pricing. Patients and insurers cover the difference. The industry calls these "reverse payment settlements" because money flows from the patent holder to the challenger, the opposite of a normal patent dispute.

The Cost

The FTC estimated pay-for-delay agreements cost the healthcare system $3.5 billion per year. A 2024 study in the Journal of Health Economics put the figure at $12 billion per year, with $3 billion paid directly by patients through higher copays and premiums. Even the conservative estimate exceeds the annual budget of many federal health programs.

Legal Status After Actavis

The Supreme Court addressed pay-for-delay in FTC v. Actavis (2013). The ruling held that reverse payment settlements are subject to antitrust scrutiny under the rule of reason. Courts must evaluate whether the payment is unjustifiably large relative to the patent's strength. The decision did not ban pay-for-delay outright. It made the agreements harder to defend but did not eliminate them.

Before Actavis, several federal circuits treated these agreements as presumptively legal. The ruling shifted the burden but left room for companies to structure settlements that survive scrutiny.

Provigil: $300 Million to Four Companies

Cephalon paid four separate generic manufacturers a combined $300 million or more to delay generic modafinil (Provigil). Teva, which later acquired Cephalon, settled the resulting FTC case in 2015 for $1.2 billion. It remains one of the largest pay-for-delay settlements in history.

Opana ER: Pay, Then Reformulate

Endo Pharmaceuticals paid $112 million or more to generic competitors to delay entry for Opana ER. The company used the delay window to reformulate the product with abuse-deterrent properties. By the time generics arrived, patients had been switched to the reformulated version, which carried its own patent protection. The payment bought time. The reformulation locked it in.

Product Hopping: Replace Before Generics Arrive

A brand-name manufacturer discontinues or de-markets the version of a drug about to face generic competition and launches a new, patent-protected version. The goal is to shift prescriptions before generics can substitute. Pharmacists can substitute a generic for a brand-name drug, but only if the two are pharmaceutically equivalent. A new formulation breaks that equivalence.

Product hopping comes in two forms. A soft switch markets the new version aggressively while keeping the old version nominally available. A hard switch pulls the old version from the market entirely, forcing patients and pharmacies onto the new one. The legal distinction between these two forms determines whether antitrust law applies.

Prilosec to Nexium: The $4 Billion Soft Switch

AstraZeneca's Prilosec (omeprazole) faced patent expiry in 2001. The company launched Nexium (esomeprazole), the S-enantiomer of the same molecule. A massive direct-to-consumer marketing campaign shifted prescriptions before generics could take hold. Nexium became a $4 billion per year drug.

A court dismissed the antitrust challenge. AstraZeneca had not removed Prilosec from the market. Patients and physicians could still choose the original. The switch was aggressive, but it was soft.

Namenda: The Hard Switch That Failed

Actavis (formerly Forest Labs) took the opposite approach with Namenda, an Alzheimer's drug. The company announced it would discontinue Namenda IR (immediate-release memantine) before generic entry, forcing patients onto Namenda XR (extended-release). This was a hard switch: the old version would no longer be available.

A federal court found this anticompetitive and issued a preliminary injunction requiring Actavis to keep Namenda IR on the market. The legal line was clear. Marketing a new version is permissible. Withdrawing the old version to prevent generic substitution crosses into antitrust territory.

QVAR: 15 Years Past Patent Expiry

Teva's QVAR inhaler demonstrates how device patents can extend monopolies indefinitely. The company executed two successive hard switches via modifications to the inhaler device, not the active ingredient. Each switch came with new device patents unrelated to the drug itself. Generic competition was delayed until 2032, more than 15 years past the original active ingredient patent expiry.

The inhaler category tells the broader story. Of $178 billion in US inhaler revenue between 2000 and 2021, $111 billion came after active ingredient patents had expired. Device patents, not drug innovation, drove the majority of revenue.

Financial Impact

Strategy Product Annual Cost
Patent thicket Humira (AbbVie) $7.6 billion
Patent thicket Imbruvica (AbbVie / J&J) $3.1 billion
Patent thicket Eylea (Regeneron) $2.5 billion
Patent thicket Enbrel (Amgen) $1.9 billion
Pay-for-delay All agreements (FTC estimate) $3.5 billion
Pay-for-delay All agreements (JHE 2024) $12 billion

These figures measure delayed savings, the additional cost patients and insurers pay because competition that should have arrived did not. For patent thickets alone, the four drugs listed above account for $15.1 billion per year in excess spending. The full category is far larger.

Regulatory Responses

Hatch-Waxman: The Law That Enabled Both Generics and Gaming

The Hatch-Waxman Act of 1984 created the ANDA (Abbreviated New Drug Application) pathway that makes generic drugs possible. It also created the mechanism companies exploit most effectively: the 30-month stay. When a brand manufacturer lists a patent in the Orange Book and sues a generic applicant for infringement, the FDA automatically delays the generic's approval for up to 30 months. Companies can trigger this stay by listing device patents, tangential method-of-use patents, and other questionable intellectual property.

FTC Enforcement

The FTC has increasingly treated patent gaming as an unfair method of competition. In May 2025, the agency challenged more than 200 improperly listed device patents across 17 products in the Orange Book. In December 2025, Teva voluntarily removed more than 200 patent listings following FTC pressure. These actions addressed the input side of the problem: if the patents are not in the Orange Book, the 30-month stay cannot be triggered.

Europe Shows a Different Outcome

The European Union's Supplementary Protection Certificate system caps patent extensions at five years plus a six-month pediatric extension. The result is measurable. Humira biosimilars were available in Europe in 2018. US patients waited until 2023, five years longer, because AbbVie's patent thicket had no European equivalent.

The comparison is direct. The same drug, made by the same company, faced competition years earlier in a market with stricter limits on patent extensions. The difference in patient cost was not a function of innovation or safety. It was a function of how many secondary patents the legal system allowed.

What Connects These Strategies

Evergreening, pay-for-delay, and product hopping serve the same purpose: extending the period during which a single company controls the price. Each exploits a different part of the system. Evergreening exploits the patent office. Pay-for-delay exploits the litigation process. Product hopping exploits the substitution rules at the pharmacy counter. Some companies, like Endo with Opana ER, use multiple strategies on the same drug.

The pricing consequences flow downstream. Monopoly pricing inflates the benchmarks that determine what patients pay. It delays generic competition that would otherwise drive prices down by 80 to 90%. It increases the cost of programs like Medicare drug price negotiation, which must negotiate against a market where competition has been artificially suppressed. And it keeps essential medications, including insulin, at prices that force rationing.

Vyera Pharmaceuticals maintained monopoly pricing on Daraprim without patents at all, using restricted distribution instead. The strategies differ, but the outcome is the same: one company controls the price, and patients pay it.